170 related articles for article (PubMed ID: 27144283)
1. Capecitabine for treating head and neck cancer.
Iqbal H; Pan Q
Expert Opin Investig Drugs; 2016 Jul; 25(7):851-9. PubMed ID: 27144283
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?
Tomao F; Caruso G; Musacchio L; Di Donato V; Petrella MC; Verrico M; Tomao S; Benedetti Panici P; Muzii L; Palaia I
Expert Opin Drug Saf; 2021 Jun; 20(6):641-650. PubMed ID: 33555963
[No Abstract] [Full Text] [Related]
3. Capecitabine in locally advanced anal cancer, do we need randomised evidence?
Chong LC; Healey T; Michele T; Price TJ
Expert Rev Anticancer Ther; 2017 May; 17(5):411-416. PubMed ID: 28277833
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
5. Oral 5-FU alternatives for the treatment of head and neck cancer.
Vokes EE; Brockstein BE; Humerickhouse R; Haraf DJ
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):35-8. PubMed ID: 9830623
[TBL] [Abstract][Full Text] [Related]
6. Overview of platinum chemotherapy in head and neck cancer.
Forastiere AA
Semin Oncol; 1994 Oct; 21(5 Suppl 12):20-7. PubMed ID: 7527591
[TBL] [Abstract][Full Text] [Related]
7. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Tahara M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine for the treatment of pancreatic cancer.
Siddiqui NS; Godara A; Byrne MM; Saif MW
Expert Opin Pharmacother; 2019 Mar; 20(4):399-409. PubMed ID: 30649964
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
14. Safety of capecitabine: a review.
Mikhail SE; Sun JF; Marshall JL
Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
16. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
[TBL] [Abstract][Full Text] [Related]
17. Revisiting induction chemotherapy for head and neck cancer. References and reviews.
Argiris A; Jayaram P; Pichardo D
Oncology (Williston Park); 2005 Jun; 19(7):932-4, 939; discussion 939-45. PubMed ID: 16053039
[TBL] [Abstract][Full Text] [Related]
18. S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?
Yoon DH; Kim SB
Expert Rev Anticancer Ther; 2010 May; 10(5):659-62. PubMed ID: 20469998
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
20. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
